SCHEMBL5040282

SCHEMBL5040282

CCC(C)NC(=O)c1cc(-c2csc(-c3cnccn3)n2)n(CC2CCCCC2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 2/20 0.42
KLK1 P06870 1/20 0.42
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TSHR P16473 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CPT2 P23786 1/20 0.35
CPT1A P50416 1/20 0.35
CPT1B Q92523 1/20 0.35
PIM1 P11309 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
LONP1 P36776 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047659 0.89 ALDH1A1 (0.42) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5039577 0.88 KLKB1 (0.42) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5044141 0.87 KLKB1 (0.48) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL6069189 0.86 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5047738 0.85 SREBF2 (0.42) KLKB1KLK1ALDH1A1CTSKMTOR
SCHEMBL5039559 0.84 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5043862 0.83 CNR1 (0.43) KLK1KDM4EALDH1A1HPGDCNR1
SCHEMBL5044983 0.82 CDC25A (0.44) KLKB1KLK1TSHRKDM4EALDH1A1
SCHEMBL5048938 0.82 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5043757 0.80 KLKB1 (0.47) KLKB1KLK1HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885KLK1 3547/4885HDAC1 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.